FOLH1 and pachyonychia congenita: For instance, researchers are testing the use of CAR T cells that target prostate-specific membrane antigen (PSMA), a protein present on PC cells, in combination with other immunotherapies to improve their effect and target the best results in fighting PC [26,27,29].